"The cancer diagnostics industry is on the cusp of substantial growth, attributed to an aging population"

eadquartered in California, USA, Harae Dx, H a medical diagnostics company is all set to introduce the next generation Artificial Intelligence AI) enabled automated multi-cancer early detection system in India, China and the US in three years-time period. Harae Dx has already secured seed funding from global investor SOSV and is in the process of securing Series A funding of 12 million. The company holds strategic patents in its core technology platform, and the development and manufacturing of the entire diagnostics system will be executed through strategic partnerships using an outsourced model. In an exclusive interview with BioSpectrum Dr Nitin Malekar, Director, Harae Dx Inc., shared his views on the effectiveness of the new technologies being offered and regulatory challenges. Edited excerpts;

- Bhagwati Prasad

What are the new technologies you are offering? 

Our game-changing, non-invasive, portable rapid cancer diagnostic system delivers reliable test results in just 30 minutes. The heart of our innovation lies in a multi-application platform, harnessing proprietary lab-in-the-box centrifugal microfluidic technology, expressly designed for the early and precise detection of an extensive array of protein and genetic biomarkers present in blood, each pertinent to various cancer types.

Harae Dx Corp.’s visionary project overcomes the inadequacies that have plagued traditional cancer screening methodologies. First and foremost, it offers a safe, non-invasive, and cost-effective alternative, abolishing the need for cumbersome procedures that often invoke anxiety and discomfort.

Secondly, our system incorporates AI-powered algorithms that have demonstrated unparalleled accuracy, dramatically reducing the prevalence of false positives and negatives that have plagued conventional screenings.

Moreover, our solution is not just cutting-edge; it’s accessible and scalable, ensuring that a broader population can benefit from the tremendous advantages of early detection. In doing so, it has the potential to save countless lives.

The Harae Dx System is more than just a medical innovation; it’s a catalyst for transformative change in cancer care. It offers the essential tools to bridge existing healthcare gaps, making mainstream and portable cancer diagnostics the new standard. Physicians, hospitals, and laboratories now have a dependable ally, enhancing decision-making, diagnostic efficiency, and screening accuracy, all while keeping costs at a minimum.